<p>(a) Animals received vehicle or m-HemaMax at an ostensible dose of 100 ng/mouse at 24 hours and 72 hours after a TBI of 8 Gy (LD<sub>86/30</sub>). (b) Animals received vehicle or a single, ostensible dose of 300 ng/mouse of m-HemaMax at 24 hours, 48 hours, or 72 hours after a TBI of 9 Gy (LD<sub>100/30</sub>). (c) Animals received vehicle or a single low dose of m-HemaMax (2 ng/mouse or 18 ng/mouse) at 24 hours after a TBI of 7.9 Gy (LD<sub>85/30</sub>). Vehicle and m-HemaMax were injected subcutaneously. Vehicle was PBS in (a) and (b) and P5.6TT in (c). The delivered m-HemaMax dose was estimated to be 10 ng/mouse in (a) and 30 ng/mouse in (b) because subsequent studies showed that the actual m-HemaMax dose delivered was approximately 10...
<p>Mice were treated with ip injection of vehicle (V), SB 203580 (SB), G-CSF (CSF), or both (C+S) af...
<p>Mice were treated with ip injection of vehicle (V), SB 203580 (SB), G-CSF (CSF), or both (C+S) af...
<p>IVM or MOX was administered to Mdr1ab(−/−) mice (6 per dose rate) or to wild-type mice (3 per dos...
<p>Animals received m-HemaMax subcutaneously at a dose of (a) 10 ng/mouse, (b) 20 ng/mouse, (c) 40 n...
<p>Animals received m-HemaMax subcutaneously at a dose of 10 ng/mouse, 20 ng/mouse, 40 ng/mouse, or ...
<p>Individual dosing groups (a) and the pooled HemaMax dosing group (b) are shown. Animals were subj...
<p>Animals were subjected to an LD<sub>50/30</sub> of TBI at day 0. Animals received subcutaneously ...
<p>The plot of plasma AUC<sub>last</sub> of m-HemaMax versus the dose administered to mice in the ab...
<p>Body weights in Kg (a and b) and in percentage (c and d) are shown for the 100 ng/Kg and 250 ng/K...
<p>(A) Time window for effective post-irradiation administration of sLP. Female ICR (CD-1®) mice (<i...
HemaMax, a recombinant human interleukin-12 (IL-12), is under development to address an unmet medica...
<p>Mice were irradiated (8Gy TBI) and survival monitored over 30 days. DMOG (100 mg/kg) or saline wa...
<p><sup>A</sup> P-value by Fisher's exact test (two-tailed) for comparisons vs. vehicle groups withi...
<p><i>TM</i><sup><i>+/+</i></sup> mice were injected subcutaneously (s.c) either with vehicle (5% Tw...
HemaMax, a recombinant human interleukin-12 (IL-12), is under development to address an unmet medica...
<p>Mice were treated with ip injection of vehicle (V), SB 203580 (SB), G-CSF (CSF), or both (C+S) af...
<p>Mice were treated with ip injection of vehicle (V), SB 203580 (SB), G-CSF (CSF), or both (C+S) af...
<p>IVM or MOX was administered to Mdr1ab(−/−) mice (6 per dose rate) or to wild-type mice (3 per dos...
<p>Animals received m-HemaMax subcutaneously at a dose of (a) 10 ng/mouse, (b) 20 ng/mouse, (c) 40 n...
<p>Animals received m-HemaMax subcutaneously at a dose of 10 ng/mouse, 20 ng/mouse, 40 ng/mouse, or ...
<p>Individual dosing groups (a) and the pooled HemaMax dosing group (b) are shown. Animals were subj...
<p>Animals were subjected to an LD<sub>50/30</sub> of TBI at day 0. Animals received subcutaneously ...
<p>The plot of plasma AUC<sub>last</sub> of m-HemaMax versus the dose administered to mice in the ab...
<p>Body weights in Kg (a and b) and in percentage (c and d) are shown for the 100 ng/Kg and 250 ng/K...
<p>(A) Time window for effective post-irradiation administration of sLP. Female ICR (CD-1®) mice (<i...
HemaMax, a recombinant human interleukin-12 (IL-12), is under development to address an unmet medica...
<p>Mice were irradiated (8Gy TBI) and survival monitored over 30 days. DMOG (100 mg/kg) or saline wa...
<p><sup>A</sup> P-value by Fisher's exact test (two-tailed) for comparisons vs. vehicle groups withi...
<p><i>TM</i><sup><i>+/+</i></sup> mice were injected subcutaneously (s.c) either with vehicle (5% Tw...
HemaMax, a recombinant human interleukin-12 (IL-12), is under development to address an unmet medica...
<p>Mice were treated with ip injection of vehicle (V), SB 203580 (SB), G-CSF (CSF), or both (C+S) af...
<p>Mice were treated with ip injection of vehicle (V), SB 203580 (SB), G-CSF (CSF), or both (C+S) af...
<p>IVM or MOX was administered to Mdr1ab(−/−) mice (6 per dose rate) or to wild-type mice (3 per dos...